Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 4/20 | 0.36 |
| ▸ | FPR2 | P25090 | 2/20 | 0.36 |
| ▸ | CMA1 | P23946 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.34 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7429087 | 0.93 | MMP2 (0.38) | FPR1CTSAPOLBCASP1SMN1; SMN2 | |
| SCHEMBL4427187 | 0.93 | MMP2 (0.38) | FPR1CTSAPOLBCASP1SMN1; SMN2 | |
| SCHEMBL4426944 | 0.91 | FPR1 (0.39) | FPR1FPR2CTSAPOLBCASP1 | |
| SCHEMBL4435242 | 0.91 | CASP1 (0.37) | FPR1FPR2CMA1CTSAPOLB | |
| SCHEMBL4426739 | 0.90 | CASP1 (0.42) | FPR1FPR2CMA1CTSACASP1 | |
| SCHEMBL8506622 | 0.90 | CTSA (0.40) | FPR1CTSACYP26A1 | |
| SCHEMBL4435400 | 0.90 | CTSA (0.40) | FPR1CTSACYP26A1 | |
| SCHEMBL4435399 | 0.90 | CTSA (0.40) | FPR1CTSACYP26A1 | |
| SCHEMBL4426794 | 0.89 | CASP1 (0.39) | FPR1CTSACASP1SMN1; SMN2GPR88 | |
| SCHEMBL4426400 | 0.89 | CYP26A1 (0.38) | FPR1CTSAGPR88CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1213288-B1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2009-01-14 | — | — | EP | disclosed |